← Back to Search

Small Molecule

Venglustat for Polycystic Kidney Disease

Phase 1
Waitlist Available
Research Sponsored by Genzyme, a Sanofi Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 10
Awards & highlights
No Placebo-Only Group

Summary

Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics (PK) of Venglustat following a single dose. Secondary Objective: To assess the tolerability of Venglustat given as a single dose in subjects with mild, moderate and severe renal impairment in comparison with matched subjects with normal renal function.

Eligible Conditions
  • Polycystic Kidney Disease
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 10
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 10 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assessment of pharmacokinetic (PK) parameters of Venglustat: Area under the curve (AUC)
Secondary study objectives
Venglustat plasma pharmacokinetic (PK) parameter: AUClast
Venglustat plasma pharmacokinetic (PK) parameter: CL/F
Venglustat plasma pharmacokinetic (PK) parameter: Cmax
+10 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: VenglustatExperimental Treatment1 Intervention
Single dose of Venglustat is given, orally under fasting conditions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Venglustat GZ/SAR402671
2018
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Genzyme, a Sanofi CompanyLead Sponsor
526 Previous Clinical Trials
185,696 Total Patients Enrolled
Clinical Sciences & OperationsStudy DirectorSanofi
871 Previous Clinical Trials
2,020,932 Total Patients Enrolled
~3 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top